墨西哥与强生及康希诺(06185.HK)等签备忘录 协助新型肺炎疫苗临床试验
墨西哥外交部表示,已与强生公司、康希诺生物(06185.HK)及云南沃森生物技术(Walvax Biotechnology)签署谅解备忘录,协助三企正在研发的新型肺炎疫苗进行後期临床试验。而康希诺与云南沃森有意在墨西哥设厂生产疫苗。
墨西哥外长埃布拉德(Marcelo Ebrard)表示,有关测试料将於今年9月至明年1月进行,取决於该国食物与药品管理局的批准,目标是确保墨西哥可获得药物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.